
Organovo Holdings ONVO
Quarterly report 2025-Q4
added 02-11-2026
Organovo Holdings DPO Ratio 2011-2026 | ONVO
Annual DPO Ratio Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.9 K | - | - | - | 801 | 476 | 164 | 447 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 82.9 K | 164 | 17 K |
Quarterly DPO Ratio Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 30.8 K | 70.2 K | 39.8 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.42 K | 107 | 180 | 582 | 500 | 386 | 392 | - | 212 | 157 | 263 | - | 318 | 72.9 | 103 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 70.2 K | 72.9 | 9.22 K |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M | ||
|
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | ||
|
Fulgent Genetics
FLGT
|
35.2 | $ 17.63 | -0.23 % | $ 543 M | ||
|
Guardant Health
GH
|
48.6 | $ 124.23 | 3.65 % | $ 15.6 B | ||
|
ICON Public Limited Company
ICLR
|
9.51 | $ 117.53 | 3.23 % | $ 9.69 B | ||
|
Agilent Technologies
A
|
50.1 | $ 116.72 | 1.43 % | $ 35.5 B | ||
|
Interpace Biosciences
IDXG
|
33 | $ 1.8 | - | $ 7.96 M | ||
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M | ||
|
Illumina
ILMN
|
56.3 | $ 146.22 | 0.69 % | $ 23.2 B | ||
|
Co-Diagnostics
CODX
|
4.24 K | $ 9.53 | 4.56 % | $ 12.7 M | ||
|
Castle Biosciences
CSTL
|
65.8 | $ 21.58 | 9.6 % | $ 626 M | ||
|
Aspira Women's Health
AWH
|
189 | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
196 | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M | ||
|
CareDx, Inc
CDNA
|
44.2 | $ 21.92 | 1.76 % | $ 1.17 B | ||
|
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | ||
|
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | ||
|
Lantheus Holdings
LNTH
|
23.6 | $ 100.07 | 0.01 % | $ 6.75 B | ||
|
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B | ||
|
Mettler-Toledo International
MTD
|
53.4 | $ 1 111.16 | 0.89 % | $ 22.9 B | ||
|
NeoGenomics
NEO
|
19.7 | $ 9.52 | 2.7 % | $ 1.22 B | ||
|
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | ||
|
National Research Corporation
NRC
|
10.1 | $ 19.5 | 2.42 % | $ 436 M | ||
|
Natera
NTRA
|
17.9 | $ 199.69 | -0.61 % | $ 19.7 B | ||
|
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | ||
|
Charles River Laboratories International
CRL
|
24.5 | $ 161.9 | 3.3 % | $ 8.02 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | ||
|
Personalis
PSNL
|
65.7 | $ 9.0 | 0.67 % | $ 803 M | ||
|
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | ||
|
Medpace Holdings
MEDP
|
13.3 | $ 433.87 | 1.11 % | $ 12.5 B | ||
|
Exact Sciences Corporation
EXAS
|
49.2 | - | - | $ 19.8 B | ||
|
Myriad Genetics
MYGN
|
45.9 | $ 3.92 | 1.82 % | $ 363 M | ||
|
Senseonics Holdings
SENS
|
68 | $ 6.45 | 0.24 % | $ 269 M | ||
|
QIAGEN N.V.
QGEN
|
50 | - | - | $ 10.6 B | ||
|
Soleno Therapeutics
SLNO
|
1.44 K | - | - | $ 2.69 B | ||
|
Biomerica
BMRA
|
32.4 | $ 2.33 | -5.67 % | $ 5.35 M | ||
|
Twist Bioscience Corporation
TWST
|
12.5 | $ 65.83 | 1.49 % | $ 3.94 B | ||
|
Laboratory Corporation of America Holdings
LH
|
31.5 | $ 262.38 | 1.52 % | $ 21.8 B | ||
|
Thermo Fisher Scientific
TMO
|
49.3 | $ 452.57 | 0.96 % | $ 171 B | ||
|
Waters Corporation
WAT
|
102 | $ 345.75 | 2.1 % | $ 20.6 B | ||
|
Trinity Biotech plc
TRIB
|
163 | $ 0.64 | -0.94 % | $ 230 M | ||
|
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | ||
|
Neogen Corporation
NEOG
|
62.7 | $ 9.37 | 2.52 % | $ 2.03 B | ||
|
Quest Diagnostics Incorporated
DGX
|
14.7 | $ 195.52 | 1.37 % | $ 21.7 B |